T he time has come to acknowledge the elephant in America's IV rooms. In many respects, the USP <797> regulations and proposed revisions are the epitome of the unfunded (and unfounded) mandate. Despite the fact that some pharmacy leaders recognize the exaggerated response associated with many aspects of these requirements, 1 it appears that the pharmacy practice community is reluctant to speak out against these standards in professional circles. While there are no doubt a number of redeeming aspects to the standards, there are many shortcomings that must be addressed before the chapter is finalized.
The patient safety impetus behind the standards is laudable, and is a result of the pharmacy community's relatively poor and inconsistent adherence to guidelines that had been available for many years. 2 Surveys conducted by the American Society of Health-System Pharmacists repeatedly demonstrated a general lack of compliance with basic patient safety precautions related to the compounding of IV admixtures. Moreover, several nationally publicized, harmful patient events-none of which have been reliably traced to U.S. hospitals-catalyzed the development of the <797> regulations. 3 To this end, the standards provide useful guidance related to microbial contamination risk lev-els, verification of compounding quality, and the delineation of responsibilities of compounding personnel.
On the other hand, the regulations are not completely grounded in scientific evidence. Many of these requirements are not only groundless, but defy common sense. An example of such arbitrage is the revised 28-day requirement for expiration dating of multi-dose vials, whose origin appears to emanate from USP Chapter <51>, which is also unsubstantiated. Sterile alcohol is no longer required for disinfection but sterile gloves are. Direct sterility testing is required to change established sterile product beyond use dates, but these tests would only apply to the samples tested and have limited bearing on future batches or individual product preparation. The medium risk, cold temperature storage period was capriciously changed in the revisions from seven to nine days. The proposed exemption of hazardous drugs for immediate use compounding consideration as it relates to an ISO Class 7 room is also illogical. Where is the evidence to support such requisites?
Of major concern, hospitals across the country have likely spent hundreds of millions of capital dollars in renovations of healthsystem IV rooms. Just imagine for a moment if this investment could have been spent on the develop-ment of evidence-based programs where pharmacists have been shown to measurably improve patient outcomes. What if the expenditures could have been used to establish bedside barcode scanning initiatives or other programs that have been recognized to improve patient safety? These resources could have been used to fund pharmacists on pain management teams, or for anticoagulation clinics, or for rounding pharmacists in critical care, or to expand pharmacy practice and specialty residency programs. It is not unrealistic to postulate that this investment could have funded enough pharmacist resources to perform medication reconciliation for every patient at virtually every hospital in the country. Instead, these funds have been expended on an effort that has done little more than improve the air that is inhaled by our IV Room staff.
Part of the progeny of these regulations has been the development of a cottage industry of consultants, engineers, and glove box purveyors whose main purpose is to capitalize on these injudicious and mandated environmental changes. Further, software has been developed and marketed to assist pharmacists in documenting and tracking the many environmental testing and sampling points required by USP, none of which have been demonstrated to improve patient care. Many state Hospital Pharmacy 1019 Editorial Boards of Pharmacy are now surveying hospital pharmacies against the details of these standards. 4 Fortunately, the Joint Commission on Accreditation of Healthcare Organizations has recanted their original position of strict enforcement of the standards, which was not in accord with their many other evidence-based initiatives. 4 There are many unintended consequences associated with USP <797>. One of the most significant and dangerous is that the regulations have shifted the national focus of IV preparation to the environment, yet proper aseptic technique is the only factor that has been consistently confirmed to improve the sterility of IV admixtures. [5] [6] [7] [8] There is not one published study that has demonstrated that the environment outside of a Class 100 (ISO Class 5) IV admixture hood has any bearing whatsoever on the sterility of the prepared product. In fact, there is evidence to support that the external environment has no impact on product sterility. The regulations have caused many pharmacists to focus primarily on the creation of cleanrooms (often at the expense of other pharmacy work areas) rather than employee training and observation of technique.
Another paradox is that recent, well publicized sterile product contaminations have occurred at two of the country's largest IV admixture compounding facilities. These companies are thought by many to exemplify the strict adher-ence to the environmental standards and testing that are required by USP, yet they still had documented product contaminations. Why? Because of failures in initial product quality, procedure compliance, employee training, and aseptic technique. Even the garb and gloves that employees wear during the compounding process has been shown to be immaterial. What ultimately matters is strict adherence to aseptic technique, appropriate procedures to assure quality ingredients, and the use of properly trained employees. When failures in these areas occur, contaminations have been shown to result regardless of the environment.
As a profession, we need to embrace and implement minimum standards for admixture compounding. It is time, however, for pharmacists to speak out about the well-intended, but unfounded sections of these regulations. Furthermore, it is time for USP to reconsider these regulations in light of the factual evidence that exists and revise them accordingly. Where evidence is not available, studies should be conducted and pertinent regulations should be reclassified as guidelines until such trials prove the need for added regulation. This is imperative. Finally, Boards of Pharmacy must reassess their enforcement plans related to both the arbitrary and environmental standards, and shift their focus to observation of adherence to appropriate aseptic technique and quality assurance measures. There is still time to address these issues, since USP does not expect to finalize the chapter until early 2007. Let's not let time run out.
